Session Details
[O-31]Oral Session 31 Dementia 3
Fri. May 23, 2025 10:15 AM - 11:45 AM JST
Fri. May 23, 2025 1:15 AM - 2:45 AM UTC
Fri. May 23, 2025 1:15 AM - 2:45 AM UTC
第08会場(大阪国際会議場12F グラントック)
Chair: Taizen Nakase（Tohoku University, Institute of Development, Aging and Cancer, Japan）
[O-31-1]Pathophysiological evaluation using EEGs and plasma AD biomarkers in a community-based cohort
Kohei Morimoto1,2, Hisatomo Kowa3, Ryosuke Takeda2, Kazuma Koda2, Kento Matoba2, Sayo Matsuura4, Harutsugu Tatebe4, Takahiko Tokuda4, Riki Matsumoto2,5 (1.Division of Integrated Analysis of Bioresource and Health Care, Kobe University Graduate School of Medicine, Japan, 2.Division of Neurology, Kobe University Graduate School of Medicine, Japan, 3.Department of Rehabilitation Science, Kobe University Graduate School of Health Sciences, Japan, 4.Advanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Japan, 5.Department of Neurology, Kyoto University Graduate School of Medicine, Japan)
[O-31-2]Predicting brain amyloid positivity on PET using a blood test for dementia screening
Noriyuki Kimura1, Kotaro Sasaki2, Teruaki Masuda1, Takuya Ataka1, Mariko Matsumoto2, Mika Kitamura2, Yosuke Nakamura2, Etsuro Matsubara1 (1.Department of Neurology, Oita University, Faculty of Medicine, Japan, 2.Eisai Co., Ltd., Japan)
1996年 大分医科大学卒業
2007年 大分大学医学部第三内科講師
2014年 大分大学医学部神経内科診療准教授
2015年 大分大学医学部神経内科准教授
2007年 大分大学医学部第三内科講師
2014年 大分大学医学部神経内科診療准教授
2015年 大分大学医学部神経内科准教授
[O-31-3]study of factors associated with apoe and white matter lesions in lecanemab subjects
Asako Ueno1, Tomohisa Yamaguchi1, Koujirou Usui1, Yasushi Takabatake2, Syohei Sonoda3, Naoko Sakuragawa4, Hironobu Mukai2 (1.Fukui Saiseikai Hospital, Japan, 2.Fukui Saiseikai Hospital, Japan, 3.Fukui Saiseikai Hospital, Japan, 4.Fukui Saiseikai Hospital, Japan)
[O-31-4]Clinical Features of Five Cases of Neuronal Intranuclear Inclusion Disease (NIID)
Kiku Uwatoko1, Hiromu Minagawa1, Yukiko Nagaishi1, Tomohiro Imamura1, Shinsuke Fujioka1, Hideo Hara1, Megumi Iwasaki2, Chisato Tamai3, Jun Sone3 (1.Department of Neurology, Takagi Hospital, Japan, 2.Department of Neurology, Karatsu Red Cross Hospital, Japan, 3.Institute for Medical Science of Aging, Aichi Medical University, Japan)
[O-31-5]Trajectories and predictors of treatment-related amyloid clearance [Encore Presentation]
Sergey Shcherbinin1, Chakib Battioui1, Shoichiro Sato2, Ivelina Gueorguieva1, Ming Lu1, Paula M. Hauck1, Mark A. Mintun1, John R. Sims1, Emily C. Collins1 (1.Eli Lilly and Company, USA, 2.Eli Lilly Japan K.K., Japan)
[O-31-6]Effect of Donanemab on ARIA-E and Amyloid Lowering in Early Symptomatic Alzheimer's Disease
Taka Matsumura1, Shoichiro Sato1, Hong Wang2, Emel Serap Monkul Nery2, Paul Ardayfio2, Rashna Khanna2, Diana Otero Svaldi2, Paula Hauck2, Sergey Shcherbinin2, Dawn A. Brooks2, Emily C. Collins2, Mark A. Mintun2, John R. Sims2 (1.Eli Lilly Japan K.K., Japan, 2.Eli Lilly and Company, USA)